Trial reportDrug design, development and therapy2026
The Median Effective Infusion Rate of Ciprofol with Different Doses of Esketamine During Gastrointestinal Endoscopy: A Randomized Controlled Trial.
Trial report in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To quantify the dose-dependent ciprofol-sparing effect of adjunctive esketamine and determine its optimal infusion rate regimen in adult patients undergoing gastrointestinal endoscopy. Methods: In this randomized, double-blind trial, 90 ASA I-III patients (aged 18-65 years) received ciprofol with esketamine (0.25 mg/kg [SK0.25], 0.5 mg/kg [SK0.5]) or saline (SK0) during combined gastroscopy/colonoscopy. The median effective infusion rate of ciprofol was determined using the modified Dixon's up-and-down method. Hemodynamic parameters and adverse events were systematically assessed. Results: Adjunctive esketamine significantly reduced ciprofol median effective infusion rate in dose-dependent manner: 0.75 mg/kg/h (95% CI: 0.66-0.85) with saline versus 0.70 mg/kg/h (0.66-0.76; adjusted Conclusion: Esketamine (0.5 mg/kg) significantly reduces the ciprofol maintenance infusion rate while enhancing hemodynamic stability during gastrointestinal endoscopy. Under standard monitoring, no hypoxemia occurred in any group. However, specific esketamine-related adverse events, such as neuropsychiatric symptoms and increased secretions, were not systematically assessed, which should be considered when interpreting the clinical safety profile. These findings are based on specific procedural and monitoring protocols; their application to different clinical settings should consider local contexts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.